Skip to content
TrialMatch
Sign up
Recruiting

Detecting Early Alzheimer's Using MR

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 10% of individuals aged ≥ 65. Most available treatments aim at controlling symptoms at an early stage rather than providing a cure. Therefore, an accurate and early diagnosis of AD with appropriate management will slow the progression of the condition. Reduced cerebral glucose levels have been observed in patients with early AD. Glucose hypometabolism can be assessed by administering a radioactive glucose analogue, 2-deoxy-2-(18F) fluoro-D-glucose (18FDG), and imaging with PET (positron emission tomography). The high cost and limited availability of PET-CT (PET - computed tomography) still hamper its general clinical application. Moreover, the use of radioactive tracers in combination with the additional ionizing radiation of CT is not suitable for repeated measurements. Therefore, currently, the provisional diagnosis of AD is still based on the combination of clinical history, neurological examination, cognitive testing over a period of time, and structural neuroimaging. This has major time and resource implications. A radically different and highly innovative means for imaging glucose with magnetic resonance imaging (MRI) has now been established, exploiting the interaction between hydroxyl protons in glucose and the protons in water; the method is termed glucose Chemical Exchange Saturation Transfer (glucoCEST). GlucoCEST MRI is a method that has no reliance on radiolabelled glucose analogues and could become widely implemented in clinic practice. We therefore aim to investigate the potential of glucoCEST MRI in Alzheimer's disease.

Condition
Alzheimer Disease
Tested
Magnetic Resonance Imaging (MRI), Blood Glucose Assessment, Positron Emission Tomography (PET), Cognitive Assessment
Sponsor
University of Aberdeen

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Accepted

Inclusion 16

  • Minimum age: 18 years
  • Study condition: Alzheimer Disease
  • Development phase:
  • Controls (development group) must:
  • be \> 18 years
  • consent to the study
  • not report problems with memory.
  • Clinical phase
  • Patients must:
  • be ≥ 65 years,
  • able to provide informed consent to the study
  • have been clinically diagnosed with AD by the mental health team.
  • Controls must:
  • be ≥ 65 years
  • able to provide consent to the study
  • have a normal score in the ADAS-cog test and the Mini Mental State Examination test (MMSE)

Exclusion 8

  • Subjects will not be considered if they:
  • have a history of diabetes,
  • have history of a major stroke (mini-stroke/Transient Ischaemic Attacks or lacunar stroke are acceptable),
  • have contra-indications to MRI scanning such as implantable cardiac devices
  • have family history in AD, to exclude possible gene mutations associated with AD
  • have advanced AD who lack the capacity to consent.
  • Are pregnant (for developmental phase)
  • are unable to read or speak English

Where

1 site, 1 recruiting

University of Aberdeen

Aberdeen, United Kingdom

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.